Immunotherapies targeting stimulatory pathways and beyond.

Autor: Marin-Acevedo JA; Department of Hematology and Oncology, H. Lee Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, 33612, FL, USA., Kimbrough EO; Division of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Road S., Jacksonville, FL, 32224, USA., Manochakian R; Division of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Road S., Jacksonville, FL, 32224, USA., Zhao Y; Division of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Road S., Jacksonville, FL, 32224, USA., Lou Y; Division of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Road S., Jacksonville, FL, 32224, USA. lou.yanyan@mayo.edu.
Jazyk: angličtina
Zdroj: Journal of hematology & oncology [J Hematol Oncol] 2021 May 12; Vol. 14 (1), pp. 78. Date of Electronic Publication: 2021 May 12.
DOI: 10.1186/s13045-021-01085-3
Abstrakt: Co-stimulatory and co-inhibitory molecules play a critical role in T cell function. Tumor cells escape immune surveillance by promoting immunosuppression. Immunotherapy targeting inhibitory molecules like anti-CTLA-4 and anti-PD-1/PD-L1 were developed to overcome these immunosuppressive effects. These agents have demonstrated remarkable, durable responses in a small subset of patients. The other mechanisms for enhancing anti-tumor activities are to target the stimulatory pathways that are expressed on T cells or other immune cells. In this review, we summarize current phase I/II clinical trials evaluating novel immunotherapies targeting stimulatory pathways and outline their advantages, limitations, and future directions.
Databáze: MEDLINE